First Author | Arcidiacono P | Year | 2018 |
Journal | Nat Commun | Volume | 9 |
Issue | 1 | Pages | 1021 |
PubMed ID | 29523849 | Mgi Jnum | J:259696 |
Mgi Id | MGI:6149256 | Doi | 10.1038/s41467-018-03470-y |
Citation | Arcidiacono P, et al. (2018) p63 is a key regulator of iRHOM2 signalling in the keratinocyte stress response. Nat Commun 9(1):1021 |
abstractText | Hyperproliferative keratinocytes induced by trauma, hyperkeratosis and/or inflammation display molecular signatures similar to those of palmoplantar epidermis. Inherited gain-of-function mutations in RHBDF2 (encoding iRHOM2) are associated with a hyperproliferative palmoplantar keratoderma and squamous oesophageal cancer syndrome (termed TOC). In contrast, genetic ablation of rhbdf2 in mice leads to a thinning of the mammalian footpad, and reduces keratinocyte hyperproliferation and migration. Here, we report that iRHOM2 is a novel target gene of p63 and that both p63 and iRHOM2 differentially regulate cellular stress-associated signalling pathways in normal and hyperproliferative keratinocytes. We demonstrate that p63-iRHOM2 regulates cell survival and response to oxidative stress via modulation of SURVIVIN and Cytoglobin, respectively. Furthermore, the antioxidant compound Sulforaphane downregulates p63-iRHOM2 expression, leading to reduced proliferation, inflammation, survival and ROS production. These findings elucidate a novel p63-associated pathway that identifies iRHOM2 modulation as a potential therapeutic target to treat hyperproliferative skin disease and neoplasia. |